Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA.
Int J Neuropsychopharmacol. 2013 Nov;16(10):2131-44. doi: 10.1017/S1461145713000606. Epub 2013 Jun 10.
One of the main obstacles faced by translational neuroscience is the development of animal models of psychiatric disorders. Behavioural pharmacology studies indicate that psychedelic drugs, such as lysergic acid diethylamide (LSD) and dissociative drugs, such as phencyclidine (PCP), induce in healthy human volunteers psychotic and cognitive symptoms that resemble some of those observed in schizophrenia patients. Serotonin 5-HT2A and metabotropic glutamate 2 receptors have been involved in the mechanism of action of psychedelic and dissociative drugs. Here we review recent advances using LSD-like and PCP-like drugs in rodent models that implicate these receptors in the neurobiology of schizophrenia and its treatment.
转化神经科学面临的主要障碍之一是精神疾病动物模型的开发。行为药理学研究表明，致幻剂，如麦角酸二乙基酰胺（LSD）和分离性药物，如苯环利定（PCP），会在健康的人类志愿者中引起类似精神分裂症患者所观察到的精神病和认知症状。5-羟色胺 5-HT2A 和代谢型谷氨酸 2 受体参与了致幻剂和分离性药物的作用机制。在这里，我们综述了使用 LSD 样和 PCP 样药物在啮齿动物模型中的最新进展，这些进展表明这些受体与精神分裂症的神经生物学及其治疗有关。
